Brief: Humacyte Announces FDA Acceptance Of Ind For First-In-Human Clinical Study Of Ctev For Coronary Artery Bypass Grafting
27/07/2026 13:09
BRIEF-Humacyte Announces FDA Acceptance Of Ind For First-In-Human Clinical Study Of Ctev For Coronary Artery Bypass Grafting July 27 (Reuters) - Humacyte Inc HUMA.O:
HUMACYTE ANNOUNCES FDA ACCEPTANCE OF IND FOR FIRST-IN-HUMAN CLINICAL STUDY OF CTEV FOR CORONARY ARTERY BYPASS GRAFTING
HUMACYTE - TO INITIATE PHASE 2A CTEV STUDY IN CABG THIS QUARTER
Source text: ID:nGNX3Gkn6z
Further company coverage: HUMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Humacyte
See all newsBrief: Humacyte Announces Lancet Digital Health Publication Of V007 Phase 3 Hemodialysis Access Trial Results
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Humacyte falls after wider-than-expected quarterly loss
Humacyte Inc reports results for the quarter ended June 30 - Earnings Summary